ArticleNature nanotechnology2019
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Article in Nature nanotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 306 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
306 citing papers in PubMed, 640 citations in OpenAlex.
- Nanoadjuvant-based membrane poration boosts antitumor immunity via modulating mitochondrial metabolism to downregulate PD-L1 and upregulate STING.Bioactive materials · 2027Article
- A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines.Materials today. Bio · 2026Review
- Chemically Regulated STING-Activating Prodrugs of Deoxyribose Cyclic Dinucleotides Elicit Robust Immune Activation and Durable Antitumor Immunity.Angewandte Chemie (International ed. in English) · 2026Article
- Cold and hot tumors: immunological determinants, cancer-immunity cycle dysregulation, and nanotechnology-driven therapeutic approaches.Molecular biomedicine · 2026Review
- Supramolecular STING-Hydrogel Spatiotemporally Boosts Tumor-Derived Extracellular Vesicle-Based Personalized Vaccine for Enhanced Cancer Immunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Engineered GLUT1-targeted STING polyproagonists: Redox-triggered activation and enhanced endosomal escape for cancer immunotherapy.Asian journal of pharmaceutical sciences · 2026Article
- Amine oxide lipid nanoparticles for delivery of cyclic dinucleotides.National science review · 2026Article
- Biomimetic self-assembled copper nanoadjuvant potentiates hepatocellular carcinoma immunotherapy via cuproptosis-driven cGAS-STING activation.Materials today. Bio · 2026Article
- Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma.Materials today. Bio · 2026Article
- Therapeutic targeting of the cGAS-STING pathway in human disease.The Journal of clinical investigation · 2026Review
- Viral capsid delivery of cGAMP enhances STING-dependent antitumor immune response.bioRxiv : the preprint server for biology · 2026Article
- ATP-fueled STING activation of manganese coordinated nanoagonist to boost antitumor immunity.Bioactive materials · 2026Article
- Development of bacterial sonosensitizer hybrid systems to enhance cancer sono-immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- cGAMP suppresses FTO expression to promote mCellular and molecular life sciences : CMLS · 2026Article
- Nanovaccines with ferroptosis, necroptosis and STING-activation for synergistic immunotherapy.Journal of experimental & clinical cancer research : CR · 2026Article
- Intermetallic nanoassemblies potentiate systemic STING activation.Science (New York, N.Y.) · 2026Article
- Targeting immune checkpoint therapy: The role of manganese in tumor immunotherapy.Cancer pathogenesis and therapy · 2026Review
- Porphyrin oriented bimetallic sonodynamic MOF for enhanced ferroptosis and cGAS-STING pathway mediated antitumor immunotherapy.Journal of nanobiotechnology · 2026Article
- Peptide Coacervates Promote Cytosolic Delivery of STING Agonists for Cancer Immunotherapy.Vaccines · 2026Article
- A biomimetic nanodisc system selectively activates type I interferons by nonclassical STING pathway for cancer immunotherapy.Nature communications · 2026Article
246 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Cyclic dinucleotide (CDN) agonists of stimulator of interferon genes (STING) are a promising class of immunotherapeutics that activate innate immunity to increase tumour immunogenicity. However, the efficacy of CDNs is limited by drug delivery barriers, including poor cellular targeting, rapid clearance and inefficient transport to the cytosol where STING is localized. Here, we describe STING-activating nanoparticles (STING-NPs)-rationally designed polymersomes for enhanced cytosolic delivery of the endogenous CDN ligand for STING, 2'3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP). STING-NPs increase the biological potency of cGAMP, enhance STING signalling in the tumour microenvironment and sentinel lymph node, and convert immunosuppressive tumours to immunogenic, tumoricidal microenvironments. This leads to enhanced therapeutic efficacy of cGAMP, inhibition of tumour growth, increased rates of long-term survival, improved response to immune checkpoint blockade and induction of immunological memory that protects against tumour rechallenge. We validate STING-NPs in freshly isolated human melanoma tissue, highlighting their potential to improve clinical outcomes of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.